MedTrace Logo

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

NCT06532058 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2024-08-01

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of QHRD107 capsule combined with Venclexta and azacitidine in the treatment of relapsed/refractory acute myeloid leukemia: a single-arm, open, multicenter Phase IIa study

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)

Interventions

DRUG

QHRD107 capsule，Venclexta and Azacitidine

QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）

Sponsors & Collaborators

  • Changzhou Qianhong Bio-pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Li Junmin, Doctor · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2025-02-10
Completion
2025-05-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06532058 on ClinicalTrials.gov